#	Pagina
attuale pagina	/open-h2020/projects/224933/index.html
-1	/open-h2020/projects/203368/index.html
-2	/open-h2020/projects/195551/index.html
-3	/open-h2020/projects/208742/index.html
-4	/open-consip/fornitori/2017/profilo-01472330420/index.html
-5	/open-consip/fornitori/2015/profilo-01458590930/index.html
-6	/open-h2020/projects/194284/index.html
-7	/open-h2020/projects/224450/index.html
-8	/open-h2020/projects/227394/index.html
-9	/open-h2020/projects/225691/index.html
-10	/open-consip/fornitori/2015/profilo-01432860938/index.html

Opendata, web and dolomites

NeutroCure SIGNED

Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

NeutroCure project word cloud

Explore the words cloud of the NeutroCure project. It provides you a very rough idea of what is the project "NeutroCure" about.

attempt boosting reactive causes drugs cell deactivation commercialization academic settings species normal multiple traps pathologic radio phenotype damaging breakthrough sme first regulation possibilities haematopoiesis cure precise ros extracellular activation neutrocure abnormal previously occurs safe patient despite neutrophils space autoimmunity contributes concentration dysregulated inflammation amplifiers cells solutions resolution oxygen positive disturbance pharmaceutical signaling myeloablation nets spatial generation polymorphonuclear time relieve aberrant trigger pathological cancer redox healthy temporal organism unexplored severe clinical paradox solution nature prodrug caused innovative drug modulation chemotherapy uncontrolled reverse realized treatment functions society tissues consists inhibits mechanisms killing proximal neutrophil leads

Project "NeutroCure" data sheet

The following table provides information about the project.

Coordinator	FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG Organization address address: SCHLOSSPLATZ 4 city: ERLANGEN postcode: 91054 website: www.uni-erlangen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Total cost	2˙999˙998 €
EC max contribution	2˙999˙998 € (100%)
Programme	1. H2020-EU.1.2.1. (FET Open)
Code Call	H2020-FETOPEN-2018-2019-2020-01
Funding Scheme	RIA
Starting year	2020
Duration (year-month-day)	from 2020-01-01 to 2024-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG Organization address address: SCHLOSSPLATZ 4 city: ERLANGEN postcode: 91054 website: www.uni-erlangen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (ERLANGEN)	coordinator	629˙000.00
2	UNIVERSITATSKLINIKUM ERLANGEN UNIVERSITATSKLINIKUM ERLANGEN Organization address address: MAXIMILIANSPLATZ 2 city: ERLANGEN postcode: 91054 website: www.uk-erlangen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (ERLANGEN)	participant	640˙000.00
3	UNIVERSITY OF SURREY UNIVERSITY OF SURREY Organization address address: Stag Hill city: GUILDFORD postcode: GU2 7XH website: www.surrey.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (GUILDFORD)	participant	410˙998.00
4	CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 city: MADRID postcode: 28029 website: www.cnic.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	400˙000.00
5	LVIVSKYI NATIONALNYI MEDYCHNYI UNIVERSYTET IMENI DANYLA HALYTSKOHO LVIVSKYI NATIONALNYI MEDYCHNYI UNIVERSYTET IMENI DANYLA HALYTSKOHO Organization address address: 69 PEKARSKA STREET city: LVIV postcode: 79010 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UA (LVIV)	participant	400˙000.00
6	REDOXIS AB REDOXIS AB Organization address address: MEDICON VILLAGE SCHEELEVAGEN 2 city: LUND postcode: 223 81 website: http://www.redoxis.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (LUND)	participant	400˙000.00
7	INSTITUT GUSTAVE ROUSSY INSTITUT GUSTAVE ROUSSY Organization address address: Rue Camille Desmoulins 39 city: VILLEJUIF postcode: 94805 website: http://www.igr.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (VILLEJUIF)	participant	120˙000.00

Map

Project objective

Reactive oxygen species (ROS) have key functions in healthy organism such as redox signaling for regulation of cell growth, triggering formation of neutrophil extracellular traps (NETs), and modulation of inflammation. Since in high concentration ROS are damaging to tissues, nature has evolved precise mechanisms to control their generation at the required time, concentration and space, proximal to their target. Disturbance of these mechanisms leads to aberrant ROS production that causes uncontrolled inflammation, occurs in myeloablation caused by radio- or chemotherapy and is a crucial feature of cancer cell phenotype as well as autoimmunity. Despite the damaging properties of ROS it is a paradox that pharmaceutical ROS amplifiers can reverse (“cure”) many pathologic features. For example, ROS-induced cancer cell killing inhibits cancer growth, ROS-induced deactivation of T-cells and NETs generation contributes to resolution of inflammation, and ROS-induced boosting of haematopoiesis can relieve myeloablation. These exciting possibilities have not been realized in clinical settings yet, since the high level of temporal and spatial control of ROS generation, required to allow for safe patient treatment, has yet not been achieved for any known drug. NeutroCure will be the first attempt to achieve a breakthrough solution to this problem. Using an innovative approach based on the multiple-trigger prodrug activation, this consortium will develop safe ROS amplifiers capable of boosting ROS specifically in abnormal polymorphonuclear neutrophils associated with cancer, uncontrolled inflammation and relevant for myeloablation without affecting normal cells. NeutroCure consists of 6 European academic partners and an SME who will promote commercialization of the new drugs. We expect that this project will have a great positive impact on the Society by providing previously unexplored treatment solutions for severe pathological conditions caused by dysregulated ROS-production.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUTROCURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUTROCURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

NARCISO (2019)

NAtuRal instability of semiConductors thIn SOlid films for sensing and photonic applications

Read More

QUEFORMAL (2019)

Quantum Engineering for Machine Learning

Read More

PREFET (2018)

Proactive FET Observatory for early trends, project building and social responsibility

Read More